UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________ FORM 10-K ____________________________________ ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 001-36257 TRAVERE THERAPEUTICS, INC. (Exact Name of Registrant as specified in its Charter) Delaware 27-484269 ...

Financial Performance - Fourth quarter 2025 net sales were $633.7 million, a slight increase from $632.2 million in Q3 2025, while full year 2025 net sales reached $2.5 billion, up from $2.2 billion in FY 2024[3][5] - Fourth quarter 2025 reported net income attributable to Century stockholders was $1.8 million, a decrease of $13.1 million sequentially, with full year 2025 net income at $41.8 million, down $295.0 million from FY 2024[4][8] - Adjusted net income for Q4 2025 was $128.2 million, a sequential improvement of $70.3 million, while full year 2025 adjusted net income was $253.8 million, an increase of $152.4 million from FY 2024[4][8] - Total net sales for the three months ended December 31, 2025, were $633.7 million, a slight increase from $632.2 million in the previous quarter and $630.9 million in the same quarter of 2024[17] - Total net sales for the twelve months ended December 31, 2025, reached $2,527.9 million, an increase from $2,220.3 million in 2024, indicating a year-over-year growth of approximately 13.8%[19] - Net income for the twelve months ended December 31, 2025, was $15.8 million, a decrease from $306.7 million in 2024[25] Profitability Metrics - Adjusted EBITDA for Q4 2025 was $170.6 million, a sequential increase of $69.5 million, and for full year 2025, it was $425.1 million, up $180.9 million compared to the previous year[6][9] - Gross profit for the same period was $90.0 million, up from $74.9 million in the previous quarter and $66.3 million in the same quarter of 2024, reflecting a gross margin improvement[17] - Operating income decreased to $40.7 million for the three months ended December 31, 2025, compared to $55.9 million in the previous quarter and $49.3 million in the same quarter of 2024[17] - Gross profit for the twelve months ended December 31, 2025, was $256.4 million, significantly higher than $172.0 million in 2024[19] - Operating income for the twelve months ended December 31, 2025, was $158.1 million, compared to $108.4 million in 2024, reflecting a year-over-year increase of approximately 45.9%[19] Cash and Liquidity - Century's liquidity position at December 31, 2025, included cash and cash equivalents of $134.2 million and total liquidity of $418.0 million[7] - Cash and cash equivalents increased to $134.2 million as of December 31, 2025, compared to $32.9 million as of December 31, 2024[21] - Cash provided by operating activities for 2025 was $183.6 million, a significant improvement from a cash used of $24.6 million in 2024[25] - The company reported a net cash increase of $99.9 million for the year, compared to a decrease of $54.6 million in 2024[27] Production and Shipments - Shipments of primary aluminum in Q4 2025 were 140,257 tonnes, a 14% decrease from Q3 2025, while full year shipments totaled 647,112 tonnes, down 5% from FY 2024[3][7] - Total shipments of primary aluminum for 2025 were 647,112 tonnes, generating sales of $2.2 billion, compared to 677,967 tonnes and $1.9 billion in 2024[29] Strategic Initiatives - The company announced a joint development agreement with Emirates Global Aluminium to build a new smelter in Oklahoma, marking the first new primary aluminum smelter in the U.S. since 1980[5] - The Mt. Holly restart project aims to bring back over 50,000 tonnes of idled production by the end of Q2 2026[5] - The company expects first quarter 2026 adjusted EBITDA to range between $215 million and $235 million, driven by improved metal pricing and regional premiums[10] Expenses and Adjustments - The company incurred a share-based compensation expense of $47.0 million in 2025, significantly higher than $11.3 million in 2024[25] - The unrealized loss on derivative instruments was $62.8 million in 2025, compared to a gain of $5.0 million in 2024[25] - The company incurred a net loss on forward and derivative contracts of $94.7 million, a significant increase from a loss of $2.5 million in the prior year[34] - Share-based compensation expenses rose to $47.0 million in 2025, compared to $15.5 million in 2024, indicating a substantial increase of 203%[34] - The impact of equipment failure at the Iceland casthouse resulted in costs of $46.6 million, which were expected to be covered by business interruption insurance[34] - The company reported a loss on extinguishment of debt amounting to $7.7 million, with no similar expense recorded in the previous year[34] - The lower of cost or NRV inventory adjustment was $10.5 million in 2025, contrasting with a gain of $6.4 million in 2024[34] - The company experienced a bargain purchase gain of $245.9 million in 2024, which was not repeated in 2025, impacting year-over-year comparisons[34] Future Outlook - Future outlook includes addressing operational inefficiencies and potential market expansions, particularly in response to recent equipment failures and natural disasters affecting production[33]

Financial Performance - Net sales for 2024 reached $3,373.0 million, an increase of 11.5% compared to $3,024.0 million in 2023 [248]. - Operating income improved to $188.8 million in 2024, up from $112.2 million in 2023, reflecting a 68.2% increase [248]. - Net income for 2024 was $112.5 million, compared to $65.7 million in 2023, representing a 71.3% growth [248]. - Net income for the year ended December 31, 2025, was $112.5 million, a significant increase from $65.7 million in 2024 and $67.8 million in 2023, reflecting a growth of 71% year-over-year [260]. - Income before income taxes for 2025 was $150.0 million, significantly higher than $88.0 million in 2024, marking an increase of 70.5% [413]. - The total income tax provision for 2025 was $(37.5) million, compared to $(22.3) million in 2024, indicating an increase in tax expenses [415]. Assets and Liabilities - Total current assets increased to $1,261.5 million in 2025 from $1,074.6 million in 2024, marking a 17.4% rise [245]. - Total liabilities rose to $1,738.7 million in 2025, up from $1,666.8 million in 2024, indicating a 4.3% increase [245]. - Stockholders' equity increased to $826.1 million in 2025, compared to $743.1 million in 2024, reflecting an 11.2% growth [245]. - Trade receivables increased to $395.2 million in 2025 from $319.7 million in 2024, representing a growth of 23.6% [313]. - Total inventories rose to $725.2 million in 2025, up from $601.9 million in 2024, marking a 20.5% increase [313]. - Property, plant, and equipment, net decreased slightly to $1,145.2 million in 2025 from $1,161.2 million in 2024, a decline of 1.4% [313]. Cash Flow and Capital Expenditures - Cash flows from operating activities decreased to $111.4 million in 2025 from $167.1 million in 2024, indicating a decline of 33.3% [260]. - Capital expenditures for 2025 were $136.9 million, down from $180.8 million in 2024, representing a reduction of 24.3% [260]. - The company reported a net cash used in investing activities of $77.8 million in 2025, compared to $174.6 million in 2024, showing a decrease of 55.5% [260]. - Cash and cash equivalents increased to $18.4 million in 2025 from $7.0 million in 2024, a significant rise of 162.9% [245]. Debt and Financing - Borrowings under the Revolving Credit Facility amounted to $653.3 million in 2025, with repayments of $631.0 million, indicating active management of debt [260]. - The company issued $500 million in 5.875% Senior Notes in 2025, enhancing its capital structure [260]. - The company redeemed $500.0 million of 4.625% Senior Notes in November 2025 at a redemption price of 100% of the principal amount, funded by proceeds from the new Senior Notes and existing cash [385]. - The interest expense for Senior Notes in 2025 was $50.7 million, an increase from $49.6 million in 2024 [391]. - The company has a future principal payment obligation of $1,072.3 million for its Senior Notes and Revolving Credit Facility as of December 31, 2025 [392]. Inventory and Accounting Changes - The company changed its inventory accounting method from LIFO to weighted average cost, impacting all periods presented in the financial statements [232]. - The company changed its inventory valuation methodology from LIFO to WAC effective January 1, 2025, to improve comparability and reflect the physical flow of goods more accurately [280]. Hedging and Risk Management - The company utilized hedging transactions to mitigate exposure to changes in energy prices and commodity costs [220]. - The company uses derivative instruments to manage commodity price, energy cost, and foreign currency risks, recorded at fair value on the balance sheets [290]. - As of December 31, 2025, the company had derivative contracts for approximately 23.9 million pounds of aluminum to hedge sales for 2026 [221]. - A $0.10/lb decrease in the LME market price of aluminum would have resulted in an unrealized mark-to-market loss of $2.5 million as of December 31, 2025 [222]. - The company is exposed to fluctuating prices of alloying metals, with a $0.10/lb decrease in zinc and copper prices resulting in an unrealized mark-to-market loss of $0.6 million as of December 31, 2025 [223]. Employee Benefits and Compensation - The total expense related to all benefit plans for 2025 is $36.1 million, slightly up from $35.0 million in 2024 [347]. - The pension plans' benefit obligation at the end of 2025 is $36.0 million, up from $30.7 million in 2024, while the OPEB obligation increased to $70.0 million from $64.7 million [336]. - The company recorded a liability of $23.8 million for estimated future payments related to the 2025 Short-Term Incentive Plans [357]. - Non-cash compensation expense for the year ended December 31, 2025, totaled $18.0 million, an increase from $13.8 million in 2024 [367]. Environmental and Remediation Activities - The company’s environmental accruals totaled $17.9 million as of December 31, 2025, reflecting ongoing remediation activities [400]. - The company expects that the implementation and ongoing monitoring of environmental remediation could occur over a period of 30 or more years [400]. Other Financial Metrics - Comprehensive income for 2024 was $118.8 million, compared to $73.1 million in 2023, representing a 62.3% increase [252]. - The total Accumulated Other Comprehensive Income (AOCI) ending balance increased to $26.8 million in 2025 from $20.5 million in 2024, reflecting a growth of 15.9% [403]. - Other income, net for 2025 was reported at $11.3 million, a decrease from $19.5 million in 2024, primarily due to lower gains on business interruption insurance recoveries [410].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________ Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32601 LIVE NATION ENTERTAINMENT, INC. (Exact name of registrant as specified in its charter) Delawar ...

Financial Performance - Inbound orders reached $11.2 billion, resulting in a backlog growth of 15% year-over-year to $16.6 billion[241] - Cash provided by operating activities increased by 84% to $1.8 billion, with free cash flow growing 113% to $1.4 billion[241] - Revenue for 2025 was $9,932.6 million, a 9.4% increase from $9,083.3 million in 2024, driven primarily by Subsea revenue growth[256] - Subsea gross profit increased by $437.3 million year-over-year, attributed to a favorable activity mix and volume increase[258] - Surface Technologies revenue increased by $3.3 million, reflecting higher activity in the Middle East, Europe, and Africa, offset by declines in North America and Latin America[257] - Income from equity affiliates increased by $25.3 million in 2025 compared to 2024, driven by higher operational activity in joint ventures[263] - Subsea revenue increased by $846.0 million (10.8%) in 2025, with significant contributions from Brazil ($433.7 million) and Norway ($211.5 million)[268][269] - Surface Technologies revenue increased by $3.3 million (0.3%) in 2025, primarily due to strong activity in the Middle East, Europe, and Africa[270] - Total inbound orders decreased to $11,156.2 million in 2025 from $11,574.6 million in 2024[274] - Total order backlog increased to $16,571.6 million in 2025, up from $14,376.3 million in 2024, with Subsea backlog rising by $2,353.6 million[276] - Cash provided by operating activities increased to $1,764.6 million in 2025 from $961.0 million in 2024, reflecting improved project mix and cash collections[282] - Free cash flow for 2025 was $1,447.4 million, significantly higher than $679.4 million in 2024[287] Shareholder Returns - Shareholder distributions more than doubled to $1.0 billion through share repurchases and dividends, with an additional $2 billion authorized for share repurchases[241] - The company reiterated its commitment to return at least 70% of free cash flow to shareholders in 2026[241] - The Board of Directors declared a quarterly cash dividend of $0.05 per share for 2025, totaling $82.3 million for the year, which annualizes to $0.20 per share[292] - The company authorized additional share repurchases of up to $2.0 billion, increasing total authorization to $3.8 billion, with $918.3 million repurchased in 2025[293] - As of December 31, 2025, the remaining repurchase authority is $2.2 billion, potentially allowing for the repurchase of approximately 48.8 million ordinary shares[294] Financial Position - As of December 31, 2025, TechnipFMC had net cash of $601.9 million, up from $272.5 million in 2024, indicating improved financial leverage[281] - The company restored its investment-grade status, enhancing financial flexibility and lowering borrowing costs[291] - The company maintains a strong balance sheet and sufficient liquidity to support business needs through growth and cyclicality[301] - The company had $2.9 billion in purchase obligations as of December 31, 2025, with over 93% being short-term commitments[298] Expenses and Costs - Selling, general and administrative expenses increased by $38.2 million year-over-year, driven by higher costs associated with support functions[260] - Restructuring, impairment, and other expenses rose to $72.8 million in 2025 from $25.8 million in 2024, primarily due to business transformation initiatives[261] - The gross profit for the year ended December 31, 2025, was positively impacted by approximately $87.0 million due to changes in contract estimates[308] - Certain projects experienced a negative impact of $115.5 million from estimated project cost changes, partially offset by $72.8 million from favorable negotiations[309] Tax and Deferred Assets - During 2025, $142.8 million was released from the valuation allowance for deferred tax assets, primarily due to anticipated utilization in Brazil and the U.S.[313] - The company continues to assess the realizability of deferred tax assets, with significant judgments affecting the valuation allowance[311] Currency and Interest Rate Exposure - A 10% increase or decrease in average exchange rates of all foreign currencies over 2025 would have changed revenue by approximately $521.7 million and income before income taxes by $65.3 million[323] - A 10% increase in the value of the U.S. dollar would have resulted in an additional loss of approximately $116.6 million in the net fair value of cash flow hedges as of December 31, 2025[325] - A 10% increase in interest rates across all tenors would lead to a decrease of $7.2 million in unrealized earnings from foreign currency forward contracts designated as cash flow hedges[326] - Material positions with exposure to interest rates are present in the United States, Brazil, the United Kingdom, Singapore, and Norway as of December 31, 2025[326] Derivative Instruments - Substantially all derivative holdings as of December 31, 2025 and 2024 consisted of foreign currency forward contracts and foreign currency instruments embedded in purchase and sale contracts[321] - The company does not hedge the translation impact on earnings from foreign currency fluctuations[323] - Gains and losses from derivative instruments designated as cash flow hedges are recorded in other comprehensive income until the underlying transactions are recognized[324] - The company manages foreign currency exposure through derivative instruments for transactions not denominated in the subsidiaries' functional currencies[324] - The effectiveness of foreign currency forward contracts designated as cash flow hedges is assessed based on changes in fair value attributable to changes in spot rates[326] - The company does not use derivative financial instruments for speculative purposes[321]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2025 Commission File Number 1-11758 (Exact name of Registrant as specified in its charter) | Delaware 1585 Broadway | | 36-3145972 | (212) 761-4000 | | --- | --- | --- | --- | | (State or other jurisdiction of | New York, NY 10036 | (I.R.S. Employer Identification No.) | (Registrant's telephone ...

Revenue Growth - For Q4 2025, revenue increased by 6.4% to $1,396.6 million compared to $1,312.6 million in Q4 2024[2] - For the full year 2025, revenue increased by 5.1% to $5,452.8 million, up from $5,187.1 million in 2024[3] - Total revenue for the three months ended December 31, 2025, was $1,396,634, a 6.4% increase from $1,312,564 in 2024[25] - Revenue for Critical Illness Recovery Hospital increased by 1.4% from $2,444,196,000 in 2024 to $2,477,814,000 in 2025[38] - Revenue for Rehabilitation Hospital grew by 16.1% from $1,110,592,000 in 2024 to $1,288,954,000 in 2025[38] Income and Earnings - Income from continuing operations, net of tax, rose 461.0% to $37.7 million in Q4 2025, compared to a loss of $10.5 million in Q4 2024[2] - Income from continuing operations, net of tax, for the year ended December 31, 2025, was $214,533, a 65.0% increase from $129,987 in 2024[28] - Net income attributable to Select Medical for the year ended December 31, 2025, was $146,219, a decrease of 31.7% from $214,038 in 2024[28] - Basic earnings per share from continuing operations for the three months ended December 31, 2025, was $0.16, compared to a loss of $0.18 in 2024[31] - Net income for 2025 was $37,742,000, a significant rise from $3,756,000 in 2024[35] Adjusted EBITDA - Adjusted EBITDA for the year 2025 was $493.2 million, down from $510.4 million in 2024[3] - Adjusted EBITDA for Critical Illness Recovery Hospital decreased by 12.0% from $301,634,000 in 2024 to $265,447,000 in 2025[41] - Adjusted EBITDA for Rehabilitation Hospital increased by 13.4% from $245,748,000 in 2024 to $278,622,000 in 2025[41] - The adjusted EBITDA margin for the rehabilitation hospital segment was 21.6% for the year ended December 31, 2025[10] - Total Adjusted EBITDA for the year 2025 is projected to be between $520,000,000 and $540,000,000[47] Cash and Shareholder Returns - A cash dividend of $0.0625 per share was declared, payable on or about March 12, 2026[14] - The company repurchased 6,375,512 shares at a cost of approximately $96.5 million during the year ended December 31, 2025[17] - Select Medical's stock repurchase program is authorized for up to $1.0 billion worth of shares until December 31, 2027[16] Operational Metrics - The rehabilitation hospital segment saw a revenue increase of 16.1% to $1,289.0 million for the year 2025[10] - The number of admissions in the Critical Illness Recovery Hospital segment increased by 3.0% to 8,950 in 2025[37] - The number of hospitals operated in the Rehabilitation Hospital segment increased from 35 to 38, reflecting a growth in capacity[37] - Number of admissions for Critical Illness Recovery Hospital rose by 1.0% from 35,784 in 2024 to 36,126 in 2025[38] - Number of patient days for Rehabilitation Hospital increased by 8.4% from 470,594 in 2024 to 510,127 in 2025[38] Financial Position - Total assets increased from $5,607,951,000 in 2024 to $5,851,589,000 in 2025, reflecting a growth of 4.3%[34] - Total liabilities rose from $3,610,856,000 in 2024 to $3,815,850,000 in 2025, marking an increase of 5.7%[34] - Net cash provided by operating activities decreased from $125,432,000 in 2024 to $64,325,000 in 2025[35] - Cash and cash equivalents at the end of the period decreased from $59,694,000 in 2024 to $26,523,000 in 2025[36] Challenges and Outlook - Select Medical expects 2026 revenue to be in the range of $5.6 billion to $5.8 billion[18] - The company anticipates challenges related to staffing shortages and increased operating costs due to economic conditions and regulatory changes[22]

Media Relations Consolidated Edison, Inc. New York, NY 10003 www.conEdison.com Exhibit 99.1 212 460 4111 (24 hours) 4 Irving Place FOR IMMEDIATE RELEASE Contact: Allan Drury February 19, 2026 212-460-4111 CON EDISON REPORTS 2025 EARNINGS NEW YORK - Consolidated Edison, Inc. (Con Edison) (NYSE: ED) today reported 2025 net income for common stock of $2,023 million or $5.66 a share compared with $1,820 million or $5.26 a share in 2024. Adjusted earnings (non- GAAP) were $2,038 million or $5.70 a share in 2025 ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or | | | For the transition period from to Commission File No. 001-34634 ICU MEDICAL, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 33-0022692 (State or Other Jurisdiction of Incorporat ...

Financial Performance - Q4 2025 Net Sales were $1.3 billion, down 2% year-over-year, primarily due to a 4% decrease in volume, partially offset by a 1% price increase and a 1% currency tailwind [7]. - Q4 2025 Net Loss attributable to Chemours was $47 million, or $0.31 per diluted share, compared to a Net Loss of $11 million, or $0.08 per diluted share in Q4 2024 [8]. - Adjusted EBITDA for Q4 2025 was $128 million, down 24% from $168 million in the prior-year quarter, driven by higher costs impacting net loss [8]. - Full year 2025 Net Sales were $5.8 billion, flat compared to the prior year, with TSS reporting record annual sales driven by higher volume and price [9]. - Full year 2025 Net Loss attributable to Chemours was $386 million, or $2.57 per diluted share, compared to Net Income of $69 million, or $0.46 per diluted share in the prior year [10]. - Adjusted EBITDA for the full year 2025 was $742 million, down from $768 million in the prior year, primarily due to lower pricing and cost absorption issues [10]. Segment Performance - TSS segment Q4 2025 Net Sales were $444 million, a 14% increase year-over-year, driven by a 10% price increase and a 3% volume increase [12]. - TiO2 segment Q4 2025 Net Sales were $561 million, an 11% decrease year-over-year, primarily due to a 6% decrease in price globally [17]. - APM segment Q4 2025 Net Sales were $312 million, a 4% decrease year-over-year, primarily driven by an 8% decrease in volume [21]. - APM segment Q4 2025 Adjusted EBITDA decreased 74% to $12 million, primarily due to a non-cash inventory charge and a less favorable product mix [23]. - APM segment full year 2025 Net Sales were $1.3 billion, a 5% decrease compared to full year 2024, primarily due to weaker global demand [25]. - Adjusted EBITDA for APM decreased 32% from the prior year to $108 million, driven by lower cost absorption and operational disruptions [25]. - Other Non-Reportable Segment had Net Sales of $50 million and Adjusted EBITDA of $8 million for the full year 2025 [26]. Cash Flow and Debt - Free Cash Flows for Q4 2025 were $92 million, reflecting a Free Cash Flow Conversion of 72%, compared to $29 million or 17% in Q4 2024 [30]. - As of December 31, 2025, consolidated gross debt was $4.2 billion, with a net leverage ratio of approximately 4.7x on a trailing twelve-month Adjusted EBITDA basis [28]. - Cash provided by operating activities was $264 million for the year ended December 31, 2025, a significant improvement from cash used of $633 million in 2024 [51]. - Cash used for investing activities was $206 million for the year ended December 31, 2025, compared to $353 million in 2024 [51]. - The company issued $748 million in new debt during the year ended December 31, 2025, compared to $606 million in 2024 [51]. Future Outlook - The Company anticipates consolidated Net Sales to increase by 3 to 5% in Q1 2026, with Adjusted EBITDA expected to range between $120 million and $150 million [31]. - The Company expects 2026 Net Sales growth in the range of 3 to 5% and Adjusted EBITDA of $800 million to $900 million [37]. - Capital expenditures for 2026 are anticipated to range from $275 million to $325 million, with Free Cash Flow Conversion above 25% [37]. - Estimated Free Cash Flows for the year ending December 31, 2026, are projected to be between $200 million and $270 million [67]. - Estimated Adjusted EBITDA for the year ending December 31, 2026, is expected to range from $800 million to $900 million [68]. - Net income attributable to Chemours for the year ending December 31, 2026, is estimated to be between $165 million and $225 million [68]. - Adjusted Net Income for the year ending December 31, 2026, is projected to be between $130 million and $180 million [68]. Legal and Environmental Charges - The company incurred restructuring and asset-related charges of $58 million for the year ended December 31, 2025, primarily related to the exit of the SPS Capstone™ business [59]. - Litigation-related charges for the year ended December 31, 2025, amounted to $320 million, significantly impacting the financial results due to various legal settlements [59]. - Environmental charges for the year ended December 31, 2025, included $93 million related to remediation expenses, reflecting ongoing liabilities [59]. Shareholder Information - Basic loss per share for the year ended December 31, 2025, was $(2.57), while adjusted diluted earnings per share were $0.95, down from $1.20 in 2024 [62]. - The weighted-average number of common shares outstanding for the year ended December 31, 2025, was approximately 150.8 million [62].